DocMorris AG

DOCM

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 11:31:03 2024-05-29 am EDT			5-day change	1st Jan Change
66.45 ^CHF	-2.92%		+5.98%	-9.90%

May. 27	Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	DP
May. 27	DOCMORRIS : Warburg Research reiterates its Buy rating	ZD

Zur Rose Group Ag Announces Revenue Results for the First Quarter 2019; Reaffirms Guidance for the Group for 2019

April 17, 2019 at 12:55 am EDT

Zur Rose Group AG announced revenue results for the first quarter 2019. For the quarter, the Group achieved an increase in revenue of 28.1% to CHF 381.1 million.

The company reaffirmed guidance for the Group for 2019. The company expects revenue of approx. CHF 1.6 billion, which equates to year-on-year growth of over 30%, with the aim of achieving break-even at the EBITDA level.

Latest news about DocMorris AG

Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	May. 27	DP
DOCMORRIS : Warburg Research reiterates its Buy rating	May. 27	ZD
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	May. 23
DOCMORRIS : Gets a Buy rating from Baader Bank	May. 22	ZD
DOCMORRIS : Gets a Sell rating from UBS	May. 21	ZD
DOCMORRIS : Sell rating from UBS	May. 16	ZD
DocMorris Names Successor to Outgoing CFO	May. 08	MT
DocMorris Launches Tender Offer for Convertible Bonds Due 2025	May. 06	MT
DOCMORRIS : Deutsche Bank remains its Buy rating	Apr. 23	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	Apr. 19	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
DOCMORRIS : Gets a Buy rating from Warburg Research	Apr. 18	ZD
DOCMORRIS : Receives a Buy rating from Berenberg	Apr. 18	ZD
DocMorris Completes CHF200 Million Convertible Bonds Offering	Apr. 18	MT
DOCMORRIS : Gets a Buy rating from Baader Bank	Apr. 17	ZD
DocMorris Issues CHF200 Million Convertible Bonds, Plans Tender Offer	Apr. 17	MT
DOCMORRIS : Deutsche Bank gives a Buy rating	Apr. 17	ZD
Swiss Stocks Flash Red as Geopolitical Risks Drag Sentiment	Apr. 16	MT
DOCMORRIS : Warburg Research reiterates its Buy rating	Apr. 16	ZD
DOCMORRIS : UBS reaffirms its Sell rating	Apr. 16	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	Apr. 16	ZD
Swiss online drug delivery firm DocMorris reports slight miss in Q1 sales	Apr. 16	RE
DocMorris' Q1 External Revenue Grows; FY24 Outlook Affirmed	Apr. 16	MT
DOCMORRIS : Jefferies keeps its Buy rating	Apr. 12	ZD
DOCMORRIS : Hauck & Aufhauser raises its recommendation to Buy	Apr. 12	ZD

Chart DocMorris AG

Duration

Period

More charts

Company Profile

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.45 CHF

Average target price

99.24 CHF

Spread / Average Target

+49.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-9.90%	909M
WALGREENS BOOTS ALLIANCE, INC.	-42.91%	12.85B
JD HEALTH INTERNATIONAL INC.	-31.59%	11.12B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-16.04%	7.31B
YIFENG PHARMACY CHAIN CO., LTD.	+14.51%	6.39B
MATSUKIYOCOCOKARA & CO.	-13.42%	5.68B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+73.90%	4.95B
NAHDI MEDICAL COMPANY	-2.48%	4.63B
CLICKS GROUP LIMITED	-6.07%	3.96B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-18.76%	3.18B

Other Drug Retailers

DocMorris AG

Equities

DOCM

CH0042615283

Drug Retailers

Zur Rose Group Ag Announces Revenue Results for the First Quarter 2019; Reaffirms Guidance for the Group for 2019

EPS Revisions